



# Antibiotics Why and Why Not 2025

## RESPIRATORY TRACT INFECTIONS

### Acute GAS Pharyngitis

Antibiotic	ADULT Dose	Cost/day
Penicillin V <sup>a</sup> 🦠	600 mg PO BID	\$0.97
Amoxicillin <sup>b</sup> 🦠	500 mg PO BID	\$0.26
Cephalexin 🦠	500 mg PO BID	\$0.35
Cefuroxime <sup>c</sup> 🦠	500 mg PO BID	\$1.66
Clarithromycin <sup>d</sup> 🦠	250 mg PO BID	\$0.82

Antibiotic	PEDIATRIC Dose	Cost/day
Penicillin V <sup>a</sup> 🦠	≤ 27 kg: 300 mg PO BID > 27 kg: 600 mg PO BID	\$0.48 \$0.97
Amoxicillin <sup>b</sup> 🦠	50 mg/kg/day PO once daily or divided BID (max 1000 mg/day)	\$0.05/kg
Cefprozil 🦠	20 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.08/kg
Cefuroxime <sup>c</sup> 🦠	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.22/kg
Clarithromycin <sup>d</sup> 🦠	15 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.14/kg

**Duration: 10 days**

<sup>a</sup> Penicillin V preferred 1st line (narrow spectrum, safe and low cost). No documented GAS resistance. No commercially available suspension.

<sup>b</sup> Amoxicillin broader spectrum than required, but option where palatable liquid preferred.

<sup>c</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>d</sup> If patient is unable to take any β-lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction). **Increased GAS resistance to macrolides.**

GAS = Group A Streptococcus

### Acute Bacterial Rhinosinusitis *Most cases are VIRAL and DO NOT require antibiotics!*

Antibiotic	ADULT Dose	Cost/day
Amoxicillin 🦠	500 – 1000 mg PO TID <sup>a</sup>	\$0.39 – 0.78
Amox/Clav <sup>b</sup> 🦠	875 mg PO BID	\$1.11
Cefuroxime <sup>c</sup> 🦠	500 mg PO BID	\$1.66
Clarithromycin <sup>d</sup> 🦠	500 mg PO BID	\$1.66
Doxycycline <sup>d</sup>	100 mg PO BID	\$0.93
<b>Duration: 5 days</b> in otherwise healthy individuals		

Antibiotic	PEDIATRIC Dose	Cost/kg/day
Amoxicillin 🦠	45-90 mg/kg/day divided PO TID (max 3000 mg/day)	\$0.05 – 0.10
Amox/Clav <sup>b</sup> 🦠 80mg/mL, 7:1 formulation	45-60 mg/kg/day divided PO TID (max 1500 mg/day) Dose based on amoxicillin	\$0.09 – 0.12
Cefprozil 🦠	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.12
Cefuroxime <sup>c</sup> 🦠	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.22
Clarithromycin <sup>d</sup> 🦠	15 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.14
<b>Duration: 5-7 days</b> 7-10 days may be considered if fever > 39°C or failure to respond to amoxicillin after 3-5 days.		

<sup>a</sup> Use higher dose if antibiotic use in past 3 months.

<sup>b</sup> Adults: Broader spectrum for amoxicillin treatment failure; Pediatrics: Broader spectrum if patient presents with fever > 39°C or fails to respond to amoxicillin after 3-5 days.

<sup>c</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>d</sup> If patient is unable to take any β-lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction). **Increased Streptococcus pneumoniae resistance to macrolides and tetracyclines.**

Expect symptoms to improve but not completely resolve at the end of antibiotic therapy. Some persistence of symptoms is NOT an indication for an immediate second antibiotic.



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line 🦠 = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## Acute Otitis Media (AOM) – PEDIATRIC (age ≥ 6 months)

Antibiotic	Dose	Cost/kg/day
Amoxicillin	45-60 mg/kg/day divided PO TID (max 3000 mg/day) 75-90 mg/kg/day divided PO BID (max 3000 mg/day) 80-90 mg/kg/day <sup>a</sup> divided PO BID-TID (max 4000mg/day)	\$0.05 – 0.06 \$0.08 – 0.10 \$0.09 – 0.10
Amox/Clav <sup>b</sup> 80mg/mL, 7:1 formulation	45-60 mg/kg/day divided PO TID (max 1500 mg/day) – Dose based on amoxicillin component	\$0.09 – 0.12
Cefprozil	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.12
Cefuroxime <sup>c</sup>	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.22
Clarithromycin <sup>d</sup>	15 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.14
Ceftriaxone <sup>c</sup>	50 mg/kg/day IM or IV once daily x <b>3 days</b> – Reserve for emergency department	Variable

**Duration: 5 days for age ≥ 2 years** if no known complications; **10 days for age 6 months to < 2 years, frequent, recurrent AOM, perforation or failed initial antibiotic**

<sup>a</sup> Consider higher dose for known/suspected drug-resistant *Streptococcus pneumoniae* (antibiotic use within past 3 months, daycare attendance, and/or unimmunized/incompletely immunized).

<sup>b</sup> Broader spectrum for amoxicillin treatment failure (symptomatic after 2-3 days of treatment).

<sup>c</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>d</sup> If patient is unable to take any  $\beta$ -lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction); **Increased *Streptococcus pneumoniae* resistance to macrolides.**

## Acute Exacerbation of COPD – ADULT

Antibiotic	Dose	Cost/day
< 4 exacerbations in the past year		
Amoxicillin	500 mg PO TID	\$0.39
Cefuroxime <sup>a</sup>	500 mg PO BID	\$1.66
SMX/TMP <sup>b,c</sup>	800 mg/160 mg (1 DS tablet) PO BID	\$0.45
Doxycycline <sup>b</sup>	100 mg PO BID	\$0.93
Clarithromycin <sup>b,d</sup>	500 mg PO BID	\$1.66
≥ 4 exacerbations in past year, or one of the following: Treatment failure <sup>e</sup> , recent antibiotics, home oxygen, or chronic systemic steroid use		
Amox/Clav	875 mg PO BID	\$1.11
Ceftriaxone <sup>a</sup>	1 g IV daily	\$12.50
Levofloxacin <sup>b,f</sup>	750 mg PO once daily	\$6.55
Moxifloxacin <sup>b,f</sup>	400 mg PO once daily	\$1.52

**Duration: 5 days** Expect symptoms to improve but not completely resolve at the end of therapy. Complete resolution may take several weeks.

<sup>a</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>b</sup> If patient is unable to take any  $\beta$ -lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction).

<sup>c</sup> Monitor kidney function and electrolytes if at risk of hyperkalemia (e.g., baseline renal dysfunction, age > 65 years, prolonged duration of SMX/TMP therapy, concomitant therapy with ACE inhibitors, angiotensin receptor blockers, or potassium sparing diuretics).

<sup>d</sup> **Macrolides are less effective** against *Haemophilus influenzae* and *Streptococcus pneumoniae*; Reserve for when unable to use other options.

<sup>e</sup> Treatment failure defined as: Clinical deterioration after 72 hours or no improvement after completion of first line treatment.

<sup>f</sup> **Reserve fluoroquinolones** for treatment failure or if unable to take other treatment options and no fluoroquinolone use in previous 3 months.



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## Community Acquired Pneumonia – ADULT

Antibiotic	Dose	Cost/day
CRB-65 score 0 plus O <sub>2</sub> sat > 92% on room air → can be managed in <b>OUTPATIENT setting</b>		
Amoxicillin <sup>a</sup>	500 mg to 1000 mg PO TID	\$0.39 – 0.78
Cefuroxime <sup>a</sup> <sup>b</sup>	500 mg PO BID	\$1.66
Doxycycline <sup>b,c</sup>	100 mg PO BID	\$0.93
Levofloxacin <sup>b,d</sup> <sup>e</sup>	750 mg PO once daily	\$6.55
Moxifloxacin <sup>b,d</sup>	400 mg PO once daily	\$1.52
CRB-65 score 1-2 → consider admission to <b>HOSPITAL (NON-ICU)</b>		
Amoxicillin <sup>b</sup>	500 mg to 1000 mg PO TID	\$0.39-0.78
Ampicillin <sup>b</sup>	2 g IV q6h	\$44.92
Cefuroxime <sup>a</sup> <sup>b</sup>	500 mg PO BID or 750 mg IV q8h	\$1.66/\$78.35
Ceftriaxone <sup>a</sup>	1 g IV once daily	\$12.50
Levofloxacin <sup>b,d</sup> <sup>e</sup>	750 mg PO/IV once daily	\$6.55/\$60.05
Moxifloxacin <sup>b,d</sup>	400 mg PO/IV once daily	\$1.52/\$43.54
<b>Atypical coverage is NOT routinely required.</b> Consider atypical coverage <i>with the addition of one of the following</i> if not receiving a fluoroquinolone and: Strong suspicion of atypical pathogens, not responding to β-lactams, age ≥ 65 years, or comorbidities (e.g., chronic heart, lung, liver, or renal disease, diabetes mellitus, alcohol dependence, or immunosuppression).		
Doxycycline	100 mg PO BID	\$0.93
Clarithromycin <sup>e</sup> <sup>b</sup>	500 mg PO BID	\$1.66
<b>Duration: 5 days</b>		
<sup>a</sup> 1 <sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction. <sup>b</sup> If unable to take any β-lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction) <sup>c</sup> <b>Increased <i>Streptococcus pneumoniae</i> resistance.</b> <sup>d</sup> <b>Reserve fluoroquinolones</b> for treatment failure (worsening after 72 hours or no response after therapy completion) or unable to take other treatment options and no fluoroquinolone use in the previous 3 months. <sup>e</sup> <b>Macrolides <u>alone are not</u> a 1<sup>st</sup> line option due to poor <i>Streptococcus pneumoniae</i> coverage.</b>		

## Community Acquired Pneumonia – PEDIATRIC (age > 3 months)

Antibiotic	Dose	Cost/kg/day
Amoxicillin <sup>a</sup> <sup>b</sup>	45-90 mg/kg/day divided PO TID (max 4000 mg/day)	\$0.05 – 0.10
Cefprozil <sup>b</sup> <sup>c</sup>	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.12
Cefuroxime <sup>c</sup> <sup>d</sup>	30 mg/kg/day divided PO BID (max 1000 mg/day)	\$0.22
Azithromycin <sup>d,e</sup>	10 mg/kg/day on <b>day 1</b> (max 500 mg/day), then 5 mg/kg/day PO daily x <b>4 days</b> (max 250 mg/day)	\$0.15 – 0.30
<b>Duration: 5 days</b>		
ADD one of the following for suspected <i>Mycoplasma pneumoniae</i> :		
Azithromycin <sup>e</sup>	10 mg/kg/day on <b>day 1</b> (max 500 mg/day), then 5 mg/kg/day PO daily x <b>4 days</b> (max 250 mg/day)	\$0.15 – 0.30
Doxycycline <sup>f</sup>	4 mg/kg/day divided PO BID x <b>7 days</b> (max 200 mg/day)	\$0.93 or less
<sup>a</sup> Use higher dose (75-90 mg/kg/day) if patient has any of the following risk factors for resistant <i>Streptococcus pneumoniae</i> : Unimmunized or incompletely immunized, daycare attendance, use of antibiotics in the preceding 3 months. <sup>b</sup> Cefprozil does NOT cover <i>Streptococcus pneumoniae</i> as well as amoxicillin and is NOT effective against <i>Chlamydomphila pneumoniae</i> and <i>Mycoplasma pneumoniae</i> . <sup>c</sup> 1st line option if patient has experienced an IgE mediated amoxicillin reaction. <sup>d</sup> If patient is unable to take any β-lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction) <sup>e</sup> <b>Increased <i>Streptococcus pneumoniae</i> resistance but covers <i>Chlamydomphila pneumoniae</i> and <i>Mycoplasma pneumoniae</i>.</b> <sup>f</sup> For children with macrolide allergy.		



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line <sup>b</sup> = May require renal dose adjustment  
 NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## ACUTE UNCOMPLICATED CYSTITIS

### Adult & Post-Pubertal Girls (Empiric)

Antibiotic <sup>a</sup>	Dose	Cost/course
<b>NO host risk factors for complicated infection<sup>f</sup></b>		
Nitrofurantoin Monohydrate/Macrocrystals <sup>b,e</sup> 🦋	100 mg PO BID x <b>5 days</b>	\$3.98
SMX/TMP <sup>c,e</sup> 🦋	800 mg/160 mg (1 DS tablet) PO BID x <b>3 days</b>	\$1.35
Cephalexin 🦋	500 mg PO QID x <b>5-7 days</b>	\$3.46 – 4.85
Fosfomycin <sup>d,e</sup>	3 g PO x <b>1 dose</b>	\$15.23
Amox/Clav 🦋 <i>If high risk of resistance</i>	875 mg PO BID x <b>5-7 days</b>	\$5.55 – 7.77
<b>Host risk factors for complicated infection<sup>f</sup> (excluding pregnancy)</b>		
Nitrofurantoin Monohydrate/Macrocrystals <sup>b,e</sup> 🦋	100 mg PO BID x <b>7 days</b>	\$5.58
SMX/TMP <sup>c,e</sup> 🦋	800 mg/160 mg (1 DS tab) PO BID x <b>7 days</b>	\$3.15
Cephalexin 🦋	500 mg PO QID x <b>7 days</b>	\$4.85
Fosfomycin <sup>d,e</sup> 🦋	3 g PO q72h x <b>2 to 3 doses</b>	\$30.46 – 45.69
Amox/Clav 🦋 <i>If high risk of resistance</i>	875 mg PO BID x <b>7 days</b>	\$7.77

<sup>a</sup> Other antibiotics are appropriate if culture confirms susceptibility. Moxifloxacin should not be used because it does not attain sufficient concentration in the urine.

<sup>b</sup> Nitrofurantoin should not be used in patients with CrCl < 30 ml/min, or pyelonephritis or prostatitis due to poor distribution into serum and tissue.

<sup>c</sup> Regular monitoring of kidney function and electrolytes are recommended for patients at risk of hyperkalemia, such as those with baseline renal dysfunction, age > 65 years, prolonged duration of SMX/TMP therapy, concomitant therapy with ACE inhibitors, angiotensin receptor blockers, or potassium sparing diuretics.

<sup>d</sup> Fosfomycin should not be used in patients with pyelonephritis due to poor distribution into serum and tissue.

<sup>e</sup> Option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>f</sup> **Risk factors:** Immunosuppression, poorly controlled diabetes, catheter use, delayed/impaired voiding, structural or functional abnormality of urinary tract, recent urogenital procedure, individuals with a penis.

### Pediatric (Empiric) - Age > 2 months

Antibiotic	Dose	Cost/kg/day
Cephalexin 🦋	50 mg/kg/day divided PO QID (max 2000 mg/day)	\$0.26
Cefixime <sup>a</sup> 🦋	8 mg/kg/day PO once daily (max 400 mg/day)	\$0.16
SMX/TMP <sup>a</sup> 🦋	8 mg/kg/day divided PO BID (max 160 mg TMP/dose) - Dose based on TMP component	\$0.21

**Duration: 5 to 7 days<sup>b</sup>**

<sup>a</sup> Option if patient has experienced an IgE mediated amoxicillin reaction

<sup>b</sup> Recommended duration if afebrile, not systemically ill, not recurrent, normal urinary tract anatomy, normal renal function and no history of resistant pathogens

### Pregnancy (Empiric)

Antibiotic	Dose	Cost/course
Cephalexin 🦋	500 mg PO QID x <b>7 days</b>	\$4.85
Nitrofurantoin <sup>a,b</sup> Monohydrate/Macrocrystals 🦋	100 mg PO BID x <b>5 days</b> <i>DO NOT USE In Late 3rd Trimester</i>	\$3.98
SMX/TMP <sup>b</sup> 🦋	800 mg/160 mg (1 DS tablet) PO BID x <b>3 days</b> <i>DO NOT USE in 1st or 3rd trimester</i>	\$1.35

<sup>a</sup> Nitrofurantoin should not be used in patients with CrCl < 30 ml/min.

<sup>b</sup> Option if patient has experienced an IgE mediated amoxicillin reaction or is unable to take any  $\beta$ -lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction).



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line 🦋 = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## SKIN & SOFT TISSUE INFECTIONS

<b>Mild</b>	No systemic signs of infection
<b>Moderate</b>	Systemic signs of infection, lymphangitis and/or rapidly advancing edge
<b>Severe</b>	SIRS*, immunocompromise, deep infection: bullae, skin sloughing; end organ dysfunction *SIRS (Systemic Inflammatory Response Syndrome) = two or more of temp > 38°C or < 36°C, respiratory rate > 24 breaths per min, heart rate > 90 beats per min, WBC > 12 or < 4 x 10 <sup>9</sup> /L

### Uncomplicated Outpatient Cellulitis – PEDIATRIC (age > 3 months)

Antibiotic	Dose	Cost/kg/day
Cephalexin <sup>a</sup> 🦠	50 mg/kg/day divided PO QID (max 4000 mg/day)	\$0.26
Cefuroxime <sup>a,b</sup> 🦠	30 mg/kg/day divided PO q12h (max 1000 mg/day)	\$0.22
SMX/TMP <sup>c</sup> 🦠	8-12 mg/kg/day divided PO BID (max 320 mg TMP/dose) – Dose based on TMP component	\$1.66
Clindamycin <sup>d</sup>	20 mg/kg/day divided PO TID (max 1800 mg/day)	\$1.66

**Duration: 5 days** if mild and quick response, otherwise **7-10 days**

<sup>a</sup> For GAS (Group A Streptococcus) and MSSA (methicillin-sensitive *Staphylococcus aureus*); does not cover MRSA (methicillin-resistant *Staphylococcus aureus*)

<sup>b</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction; does not cover MRSA.

<sup>c</sup> For community acquired MRSA & MSSA (does NOT cover GAS) if experienced IgE mediated amoxicillin reaction or unable to take any β-lactams (history of a delayed, severe, non-IgE-mediated hypersensitivity reaction).

<sup>d</sup> For GAS if unable to take any β-lactam (e.g., history of delayed, severe, non-IgE-mediated hypersensitivity reaction).

### Cellulitis/Erysipelas – ADULT

Antibiotic	Dose	Cost/day
<b>MILD</b>		
Cephalexin 🦠	500-1000 mg PO QID	\$0.69 – 1.38
Cefuroxime <sup>a</sup> 🦠	500 mg PO BID	\$1.66
Clarithromycin <sup>b</sup> 🦠	500 mg PO BID	\$1.66

**Duration: 5 days** if mild and quick response, otherwise **7 days**

<b>MODERATE</b>		
Cefazolin <sup>a,c</sup> 🦠	Inpatient: 2 g IV q8h Outpatient: 2 g IV q12-24h <sup>d</sup> & 1 g probenecid PO 30 min before	\$16.18 \$10.78 + probenecid
Cloxacillin <sup>c</sup>	2 g IV q4h	\$191.28
Ceftriaxone <sup>c</sup>	1 g IV q24h	\$12.50
Daptomycin <sup>b,c</sup> 🦠	4-6 mg/kg IV q24h – Dose based on adjusted body weight <sup>e</sup> in people with obesity; round to nearest 50 mg	\$97.41 - 146.12/75 kg
Vancomycin <sup>b,c</sup> 🦠	15 mg/kg IV Q12h – Round to nearest 250 mg; max 2 g/dose	\$219.32/75 kg

**Duration: 7 days**

<sup>a</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>b</sup> Option if unable to take any β-lactam (e.g., history of a delayed, severe, non-IgE mediated hypersensitivity reaction)

<sup>c</sup> May transition to PO therapy when systemic symptoms are resolved for at least 24 hours (unless *Staphylococcus aureus* bacteremia); NOTE: Oral cloxacillin is poorly tolerated and absorbed and should not be used.

<sup>d</sup> q12h interval preferred for people with obesity or significant inflammation

<sup>e</sup> Adjusted body weight = Ideal body weight (IBW) + 0.4 x (actual body weight – IBW); IBW in men = 50 kg + 2.3 kg x (height in inches – 60) and IBW in women = 45.5 kg + 2.3 kg x (height in inches – 60)



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line 🦠 = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## Purulent Skin & Soft Tissue Infections – ADULT

Cutaneous abscesses, furuncles, carbuncles → Incision and drainage (I & D) are the cornerstone of management; antibiotics do not replace the need for I & D.

Antibiotic	Dose	Cost/day
<b>NO MRSA CONCERNS<sup>a</sup></b>		
<b>MILD</b> with abscess diameter ≤ 2 cm		
No antibiotics required		
<b>MILD</b> with abscess diameter > 2 cm or other indication for antibiotic <sup>b</sup>		
Cephalexin	500 mg – 1000 mg PO QID	\$0.69 – 1.38
SMX/TMP <sup>c</sup>	1-2 DS tabs PO BID (1 DS tab = 800mg SMX/160mg TMP) Higher dose preferred if weight > 70 kg & no contraindications	\$0.45 – 0.90
Doxycycline <sup>c</sup>	100 mg PO BID	\$0.93
Clindamycin <sup>c</sup>	300-450 mg PO QID	\$1.88 – 2.82
<b>MODERATE</b>		
Cefazolin <sup>d,e</sup>	Inpatient: 2 g IV q8h Outpatient: 2 g IV q12h & 1 g probenecid PO 30 min before	\$16.18 \$10.78 <sup>+</sup> Probenecid
Vancomycin <sup>c,e</sup>	15 mg/kg IV q12h – Round to nearest 250 mg; max 2 g/dose	\$42.26/75 kg
Daptomycin <sup>b,d</sup>	4-6 mg/kg IV q24h – Dose based on adjusted body weight <sup>g</sup> in people with obesity; round to nearest 50 mg	\$97.41-146.12/75/kg
<b>MRSA CONCERNS<sup>a</sup></b>		
<b>MILD</b> with abscess diameter ≤ 2 cm		
No antibiotics required		
<b>MILD</b> with abscess diameter > 2 cm or other indication for antibiotic <sup>b</sup>		
SMX/TMP <sup>c</sup>	1-2 DS tabs PO BID (1 DS tab = 800mg SMX/160mg TMP) Higher dose preferred if weight > 70 kg & no contraindications	\$0.45 – 0.90
Doxycycline <sup>c</sup>	100 mg PO BID	\$0.93
Clindamycin <sup>c,f</sup>	300-450 mg PO QID	\$1.88 – 2.82
<b>MODERATE</b>		
Vancomycin <sup>c,e</sup>	15 mg/kg IV q12hr – Round to nearest 250 mg; max 2 g/dose	\$42.26/75 kg
Daptomycin <sup>c,e</sup>	4-6 mg/kg IV q24h – Dose based on adjusted body weight <sup>g</sup> in people with obesity; round to nearest 50 mg	\$97.41-146.12/75 kg
<b>Duration: 7-10 days</b>		
<sup>a</sup> MRSA (methicillin-resistant <i>Staphylococcus aureus</i> ) risk factors include: History of MRSA colonization or infection, recent hospitalization, injection drug use, poor response to initial antibiotics. <sup>b</sup> May add antibiotic therapy if: Multiple abscesses, lack of response to I & D alone (current or in past), surrounding cellulitis, located in an area where I & D difficult (face, hands or groin), extremes of age, impaired host defenses, indwelling medical device at a non-contiguous site isolated from infected field (e.g. pacemaker, vascular graft). <sup>c</sup> Option if unable to take any β-lactams (e.g. history of a delayed, severe, non-IgE-mediated hypersensitivity reaction). <sup>d</sup> 1 <sup>st</sup> line option if patient experienced an IgE-mediated amoxicillin reaction. <sup>e</sup> May transition to oral therapy when systemic symptoms are resolved for at least 24 hours (in absence of <i>Staphylococcus aureus</i> bacteremia) <sup>f</sup> Clindamycin remains an option for community-acquired MRSA which is more susceptible than hospital-acquired strains. <sup>g</sup> Adjusted body weight = ideal body weight (IBW) + 0.4 x (actual body weight - IBW); IBW (men) = 50 kg + 2.3 kg x (height in inches – 60) and IBW (women) = 45.5 kg + 2.3 kg (height in inches – 60)		



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line = May require renal dose adjustment  
 NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>







# Antibiotics Why and Why Not 2025

## INFECTIVE ENDOCARDITIS PROPHYLAXIS BEFORE DENTAL PROCEDURES

✗ **NOT recommended** for *most* people with a cardiovascular condition or prosthetic joint.

✓ **Recommended** for patients undergoing procedures involving manipulation of gingival tissue, dental periapical regions, or perforation of oral mucosa with one of the following:

- Prosthetic cardiac valve or material
- History of endocarditis
- History of cardiac transplantation with subsequent development of cardiac valvulopathy
- Unrepaired cyanotic congenital heart disease (CHD), including palliative shunts/conduits
- Completely repaired CHD with prosthetic material or device during 6 months following procedure
- Repaired CHD with residual defects at site of or adjacent to site of a prosthetic patch or device
- Surgical/transcatheter pulmonary artery valve or conduit placement such as Melody valve and Contegra conduit

Prophylaxis consists of a single dose of antibiotic given 30 to 60 min before the procedure.

Antibiotic	ADULT Dose	Cost	PEDIATRIC Dose	Cost
ORAL REGIMEN				
Amoxicillin	2 g PO	\$0.52	50 mg/kg (max 2000 mg) PO	\$0.05/kg
Cefuroxime <sup>a</sup>	500 mg PO	\$0.83	10 mg/kg (max 500 mg) PO	\$0.07/kg
Doxycycline <sup>b</sup>	100 mg PO	\$0.47	2.2 mg/kg (max 100 mg) PO	\$0.46 or less
UNABLE TO TAKE ORAL MEDICATION				
Ampicillin	2 g IV	\$11.23	50 mg/kg (max 2000 mg) IV	\$0.28/kg
Ceftriaxone <sup>a</sup>	1 g IV	\$12.50	50 mg/kg (to max 1000 mg) IV	\$0.62/kg
Clindamycin <sup>b,c</sup>	600 mg IV	\$15.88	20 mg/kg (to max 600 mg) IV	\$0.53/kg
<sup>a</sup> 1 <sup>st</sup> line option if patient has experienced an IgE-mediated amoxicillin reaction. <sup>b</sup> Option if patient is unable to take any $\beta$ -lactam (e.g., history of a delayed, severe, non-IgE-mediated hypersensitivity reaction). <sup>c</sup> <b>Reserve</b> for when every alternative is contraindicated due to high risk of <i>C. difficile</i> infection associated with clindamycin use. <b>The American Heart Association no longer recommends clindamycin for this use.</b>				

## DENTAL ABSCESS with Systemic Symptoms – ADULT

Antibiotic	Dose	Cost/day
Amoxicillin	500 mg PO TID	\$0.39
Penicillin VK	300-600 mg PO QID	\$0.97 – 1.94
Cefuroxime <sup>a</sup>	500 mg PO BID	\$1.66
Doxycycline <sup>b,c</sup>	100 mg PO BID	\$0.93
If little improvement after 48 hours, consider additional anaerobic coverage		
Metronidazole	500 mg PO BID	\$1.86
<b>Duration: 5 days</b> as adjunct to definitive, conservative dental treatment (may discontinue 24 hours after symptoms resolve)		
<sup>a</sup> 1 <sup>st</sup> line option if patient has experienced an IgE-mediated amoxicillin or penicillin reaction. <sup>b</sup> Option if patient is unable to take any $\beta$ -lactam (e.g., history of a delayed, severe, non-IgE-mediated hypersensitivity reaction). <sup>c</sup> Doxycycline has less activity for oral pathogens compared to $\beta$ -lactams.		

✗ Alternatives of **last resort** include **macrolides** (local high resistance rates to oral pathogens) and **clindamycin** (high risk of *C. difficile* infection).

✗ **Cephalexin** is **not recommended** by local antimicrobial stewardship experts due to poor Viridans group streptococci coverage.

✗ Amox/Clav is excessively broad spectrum for this indication. Amoxicillin + metronidazole is preferred.



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line = May require renal dose adjustment  
 NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## TICK BORNE INFECTIONS

Guidance for Primary Care and Emergency Medicine Providers in the Management of Lyme Disease, Human Granulocytic Anaplasmosis, Babesiosis and Powassan virus infection:  
<https://novascotia.ca/dhw/cdpc/infectious-disease-expert-group.asp>

## LYME DISEASE

**ANTIBIOTIC PROPHYLAXIS** is recommended when all the following are met:

- ✓ Dose can be given within 72 hours of removal of a high-risk tick
- ✓ Tick was attached for  $\geq 36$  hours
- ✓ Tick identified as adult or nymphal blacklegged tick (*Ixodes* spp.)
- ✓ Tick bite occurred in an endemic area, which includes all of NS

### ANTIBIOTIC PROPHYLAXIS Options

**Adults:** Doxycycline 200 mg PO as a single dose

**Children:** Doxycycline 4 mg/kg to max 200 mg PO round to nearest 25 mg (1/4 tablet) as a single dose OR wait-and-watch approach

✗ Amoxicillin is **not** recommended due to its short half-life.

### Treatment – ADULT Lyme Disease

Syndrome	Dose	Duration	Cost/Course
<b>Erythema migrans</b> Large (> 5cm), painless, non-pruritic, oval, solid or bull's eye erythematous rash	Doxycycline* 100 mg PO BID	10 days	\$9.30
	Amoxicillin 500 mg PO TID 🦋	14 days	\$5.46
	Cefuroxime 500 mg PO BID 🦋	14 days	\$23.24
	Azithromycin 500 mg PO once daily - Alternative if other antibiotics contraindicated	7 days	\$13.17
<b>Cranial Nerve Palsy</b> (e.g., Facial nerve palsy)	Doxycycline* 100 mg PO BID	14-21 days	\$13.02 – 19.53
<b>Meningitis or radiculopathy</b> IV therapy for severe disease, including encephalitis	Doxycycline* 100 mg PO BID	14-21 days	\$13.02 – 19.53
	Ceftriaxone 2 g IV daily	14-21 days	\$482.79 - 724.18
<b>Lyme disease-related parenchymal involvement of the brain or spinal cord</b>	Consult Infectious Diseases Service		
<b>Carditis</b> Consider ID consult	Ceftriaxone 2 g IV daily	14-21 days	\$482.79 - 724.18
	Doxycycline* 100 mg PO BID	14-21 days	\$13.02 – 19.53
	Amoxicillin 500 mg PO TID 🦋	14-21 days	\$5.46 – 8.19
	Cefuroxime 500 mg PO BID 🦋	14-21 days	\$23.24 – 34.86
<b>Arthritis (initial)</b>	Doxycycline* 100 mg PO BID	28 days	\$26.04
	Amoxicillin 500 mg PO TID 🦋	28 days	\$10.92
	Cefuroxime 500 mg PO BID 🦋	28 days	\$46.48
<b>Arthritis (recurrent or refractory)</b> Refer to rheumatology if no improvement after 8 weeks of total treatment including trial of IV therapy	Ceftriaxone 2 g IV once daily	14 days May extend to 28 days if inflammation not resolving	\$482.79 – 724.18
	Doxycycline* 100 mg PO BID	28 days	\$26.04
	Amoxicillin 500 mg PO TID 🦋	28 days	\$10.92
	Cefuroxime 500 mg PO BID 🦋	28 days	\$46.48

\*A systematic review of doxycycline use in pregnancy found no increased risk of teratogenicity, permanent teeth staining, hepatotoxicity or permanent inhibitory effects on bone growth in the developing fetus (Opin Drug Saf. 2016 <https://doi.org/10.1517/14740338.2016.1133584>).



Treatment Options: Green = 1<sup>st</sup> line Yellow = 2<sup>nd</sup> line Orange = 3<sup>rd</sup> line 🦋 = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>







# Antibiotics Why and Why Not 2025

## Treatment – PEDIATRIC Lyme Disease

Syndrome	Age (years)	Dose	Duration	Cost/Course
<b>Erythema migrans</b> Single or multiple, no neurological or cardiac signs or symptoms	≥ 8	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	10 days	\$9.12 or less
	< 8	Amoxicillin 50 mg/kg/day PO divided q8h (max 1.5 g/day)	14 days	\$0.76/kg
	All pediatrics	Cefuroxime 30 mg/kg/day PO divided q12h (max 1 g/day) <sup>a</sup>	14 days	\$3.08/kg
<b>Isolated facial palsy<sup>b</sup></b> Consult ID	All pediatrics	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	14 days	\$12.77 or less
<b>Meningitis</b> Consult ID	All pediatrics	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	14 days	\$12.77 or less
	All pediatrics	Ceftriaxone 50-75 mg/kg/day IV q24h (max 2 g/day)	14 days	\$8.68 – 13.12/kg
<b>Carditis or Atrioventricular block</b> Consult ID	≥ 8	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	14-21 days	\$6.38 (or less) – 19.15
	< 8	Amoxicillin 50 mg/kg/day PO divided q8h (max 1.5 g/day)	14-21 days	\$0.76 – 1.14/kg
	< 8	Ceftriaxone <sup>c</sup> 50-75 mg/kg/day IV q24h (max 2g/day)	14-21 days	\$8.68 – 19.68/kg
	All pediatrics	Cefuroxime 30 mg/kg/day PO divided q12h (max 1 g/day)	14-21 days	\$3.01 – 4.52/kg
	All pediatrics	Ceftriaxone <sup>c</sup> 50-75 mg/kg/day IV q24h (max 2 g/day)	14-21 days	\$8.68 – 19.68/kg
<b>Lyme Arthritis, Initial</b> Consult ID or Rheumatology	≥ 8	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	28 days	\$25.52 or less
	< 8 <sup>d</sup>	Amoxicillin 50 mg/kg/day PO divided q8h (max 1.5 g/day)	28 days	\$1.52/kg
	All pediatrics	Cefuroxime 30 mg/kg/day PO divided q12h (max 1 g/day)	28 days	\$6.02/kg
<b>Lyme Arthritis, Persistent</b> Consult ID or Rheumatology	≥ 8	Doxycycline 4.4 mg/kg/day PO divided q12h (max 200 mg/day) round to nearest 25 mg = 1/4 tablet	28 days	\$25.52 or less
	< 8 <sup>d</sup>	Amoxicillin 50 mg/kg/day PO divided q8h (max 1.5 g/day)	28 days	\$1.52/kg
	All pediatrics	Cefuroxime 30 mg/kg/day PO divided q12h (max 1 g/day)	28 days	\$6.02/kg
	All pediatrics	For <i>worsening</i> arthritis: Ceftriaxone 50-75 mg/day IV q24h (max 2 g/day)	14-28 days	\$8.68 – 26.24/kg

<sup>a</sup> 1<sup>st</sup> line option if patient has experienced an IgE mediated amoxicillin reaction.

<sup>b</sup> Amoxicillin has not been studied for treatment of facial palsy related to Lyme disease.

<sup>c</sup> Once stable and symptoms have resolved, may change to oral therapy to finish the course.

<sup>d</sup> There are limited safety data on the use of doxycycline for more than 21 days in children < 8 years of age

**HUMAN GRANULOCYTTIC ANAPLASMOSIS (HGA)** - 90% of cases have ≥ 1 of the **classic triad** signs: thrombocytopenia, leukopenia, or ↑ aminotransferase levels.

### Adult HGA

*Doxycycline 100 mg PO BID x 10 days*

- Expect rapid response within 24-48 hours of treatment
- Alternative (mild cases): Rifampin\* 300 mg PO BID x 7 to 10 days
- Consult ID if PO doxycycline contraindicated

### Pediatric HGA (including age < 8 years)

*Doxycycline 4.4 mg/kg/day PO divided BID (max 100 mg/dose) x 10 days*

- Alternative (mild cases): Rifampin\* 20 mg/kg PO divided BID (max 300 mg/dose) x 7-10 days
- Consider consulting ID

\*Limited supporting evidence, significant side-effects and drug interactions, and in cases of co-infection not effective for Lyme disease. ✗ *Beta-lactams are NOT effective*



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line 🦋 = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## CLOSTRIDIoidES DIFFICILE INFECTION (CDI) – ADULT

Category	Antibiotic	Dose	Cost/Course
First Episode	Vancomycin	125 mg PO QID x <b>10 days</b>	\$207.20
	Metronidazole	500 mg PO TID x <b>10 days</b> For mild-moderate <sup>a</sup> CDI when cost of vancomycin is prohibitive	\$27.90
First Recurrence (2 <sup>nd</sup> episode) Mild to moderate <sup>a</sup>	Vancomycin	125 mg PO QID x <b>14 days</b>	\$290.08
	Fidaxomicin <sup>b</sup>	200 mg PO BID x <b>10 days</b> For high risk of recurrence <sup>c</sup> and when cost not prohibitive	\$2052.82
	Metronidazole	500 mg PO TID x <b>14 days</b> When initial episode was not treated with metronidazole and when cost of vancomycin & fidaxomicin is prohibitive	\$39.06
First Recurrence (2 <sup>nd</sup> episode) Severe, uncomplicated <sup>d</sup>	Vancomycin	125 mg PO QID x <b>14 days</b>	\$290.08
	Fidaxomicin <sup>b</sup>	200 mg PO BID x <b>10 days</b> For high risk for recurrence <sup>c</sup> and when cost not prohibitive	\$2052.08
Second or Subsequent Recurrence (3 <sup>rd</sup> episode)	Vancomycin Taper	<ul style="list-style-type: none"> <li>• 125 mg PO QID x 14 days then</li> <li>• 125 mg PO TID x 7 days then</li> <li>• 125 mg PO BID x 7 days then</li> <li>• 125 mg PO daily x 7-14 days then</li> <li>• 125 mg PO every 2 or 3 days x 2-8 weeks</li> </ul>	\$533.54 – 688.66
	Fidaxomicin <sup>b</sup>	200 mg BID for <b>10 days</b>	\$2052.82

<sup>a</sup> Mild to moderate CDI = WBC ≤ 15 x 10<sup>9</sup>/L and creatinine ≤ 1.5 times baseline and age ≤ 60 years.

<sup>b</sup> There is increased risk of fidaxomicin hypersensitivity with history of macrolide allergy.

<sup>c</sup> Risk factors for recurrent CDI: age > 60 years, significant immunocompromise, hospitalization for severe CDI within previous 3 months, and current use of antibiotics, proton pump inhibitors, antimotility agents & opioids.

<sup>d</sup> Severe, uncomplicated CDI = WBC > 15 x 10<sup>9</sup>/L or creatinine > 1.5 times baseline or age > 60 years or hypoalbuminemia.

## CDI considerations for children

✗ “Don’t routinely collect or process specimens for *C. difficile* testing in infants < 1 year of age with diarrhea.” *Choosing Wisely Canada*

- Up to 36% of infants are asymptomatic carriers; clinical illness rarely reported before age 1-2 years.
- Limit testing to immunosuppressed infants or those with underlying intestinal conditions when other etiologies have been ruled out.
- Refer to IWK Firstline for CDI treatment of older children.



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line **👤** = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## BETA (β)-LACTAM ALLERGY ASSESSMENT

Appropriate management is based on type of allergic reaction

Reaction	Management
<b>Hypersensitivity</b> IgE mediated (within 2 hours, e.g., anaphylaxis)	<ul style="list-style-type: none"> <li>• <b>Avoid</b> reaction-provoking drug</li> <li>• <b>Choose</b> β-lactam with different side chain</li> <li>• Consider further evaluation of allergy status when feasible</li> </ul>
<b>Hypersensitivity</b> Non-IgE-mediated (delayed > 72 hours)	<b>Non-serious</b> (more common) <ul style="list-style-type: none"> <li>• <b>Choose</b> β-lactam with different side chain</li> <li>• Direct oral challenge (if feasible)</li> <li>• Consider further evaluation of allergy status when feasible</li> </ul>
	<b>Serious/life threatening</b> (rare) e.g., Stevens-Johnson syndrome <ul style="list-style-type: none"> <li>• <b>Avoid</b> all β-lactams</li> </ul>
<b>Non-hypersensitivity</b> (adverse drug event)	<ul style="list-style-type: none"> <li>• Not a contraindication</li> </ul>

### When to consider referral to an Allergist

- ✓ If unable to rule in/out an IgE mediated allergy.
- ✓ For moderate to high-risk patients, penicillin skin testing may be considered before the challenge.

Adult	Adult & Pediatric	Pediatric
Drug Allergy Clinic Bayer's Lake Community Outpatient Centre f: 902-473-8430	Halifax Allergy and Asthma Associates 5657 Spring Garden Road, Suite 503 Halifax, NS, B3J 3R4 t: 902-425-3927 f: 902-425-3928	IWK Allergy Clinic t: 902-470-6554 f: 902-470-7308  East Coast Allergy Dr. Laura Murphy 4 Forest Hills Parkway, Cole Harbour t: 902-435-5530 (ext. 10) f: 1-833-333-2679

- X Do not avoid all β-lactams** in all patients reporting penicillin allergies.
- ~10% of the population is labelled as penicillin allergic, but ~98% of these individuals are β-lactam tolerant when assessed appropriately.

**Cross-reactivity risk between penicillins and cephalosporins is low and among cephalosporins is rare** and dependent on side-chain similarities.



### Probable beta-lactam IgE mediated cross-reactivities based on side chain similarities

	Penicillin	Amoxicillin	Ampicillin	Cloxacillin	Piperacillin	Cephalexin	Cefadroxil	Cefazolin	Cefoxitin	Cefaclor	Cefprozil	Cefuroxime	Cefotaxime	Ceftriaxone	Cefixime	Ceftazidime	Meropenem	Ertapenem
Penicillin		X	X	X	X	X	X		X									
Amoxicillin	X		X	X	X	X	X			X	X							
Ampicillin	X	X		X	X	X	X			X	X							
Cloxacillin	X	X	X		X													
Piperacillin	X	X	X	X		X	X			X	X							
Cephalexin	X	X	X		X		X			X	X							
Cefadroxil	X	X	X		X	X				X	X							
Cefazolin																		
Cefoxitin	X											X						
Cefaclor		X	X		X	X	X				X							
Cefprozil		X	X		X	X	X			X								
Cefuroxime									X				X	X	X	X		
Cefotaxime												X		X	X	X		
Ceftriaxone												X	X		X	X		
Cefixime												X	X	X		X		
Ceftazidime												X	X	X	X			
Meropenem																	X	
Ertapenem																	X	

**X: Risk of IgE mediated cross reaction, use alternative**



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line **⚡** = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>





# Antibiotics Why and Why Not 2025

## Questions to ask during allergy assessment

- What medication was prescribed and what was the indication and route of administration?
- Has the medication been taken since? If so, was there a reaction?
- How long ago was the reaction?
  - Reactions in childhood or > 10 years in past may be less concerning.
- How many doses were taken prior to onset of reaction?
- How soon after the dose was taken did the reaction occur?
- Was the medication stopped? How was the reaction managed? How long did symptoms last?
- Were other medications taken at the same time?
- What was the nature of the reaction (e.g., onset) and associated signs and symptoms?

## Beta-Lactam Allergy Assessment & Penicillin De-Labeling Tools

- Assessment & de-labeling guidance tools are available through:
    - **IWK Firstline** (pediatrics & women's health)
    - **NS Health Firstline** (adults)
- \*Access Firstline via web-based (links) or mobile download (QR codes)*
- **PEN-FAST** (adults)
    - A point-of-care risk assessment tool to identify *adults at low risk* of penicillin allergy.
    - <https://www.mdcalc.com/calc/10422/penicillin-allergy-decision-rule-pen-fast>

## Direct Oral Challenge

- ✓ Gold standard test to clarify allergy status in **low-risk people** (e.g. history of a non-severe reaction 10 years or more prior) as identified via tools listed above
- ✓ Anaphylaxis management protocol and supplies required

### Single Step:

- One full dose followed by 60 minutes observation
  - Adults: Amoxicillin 500mg PO once
  - Children: Amoxicillin 15-30 mg/kg/dose PO once (max 500 mg/dose)
    - May use chewable tablets for convenience and cost

### Graded:

- Administer 10% of therapeutic dose + 30 minutes observation.
- If no symptoms occur after 30-minute observation, administer remaining 90% of therapeutic dose and observe for an additional 60 minutes.

This document is not intended to be all-inclusive. Please refer to the Academic Detailing document "Antibiotics Why and Why Not 2025":

<https://medicine.dal.ca/departments/core-units/cpd/programs/academic-detailing-service/AC-Service-Resources.html> for full content and references.

**Disclaimer:** The information contained in this document, and related presentations made by representatives of Dalhousie University's Academic Detailing Service and the Nova Scotia Health Authority, Drug Evaluation Unit, is intended for educational purposes only, and is not intended as a substitute for the advice or professional judgment of a health care professional. Although care has been taken in preparing this content, neither Dalhousie University, Nova Scotia Health Authority, nor any other involved parties warrant or represent that the information contained herein is accurate or complete. Health care professionals are required to exercise their own clinical judgement in applying this information to individual patient care. Any use of this document will imply acknowledgement of this disclaimer and release Dalhousie University, Nova Scotia Health Authority, and any party involved with the preparation of this document from any and all liability. Permission to use, copy, and distribute this material for all non-commercial and research purposes is granted, provided the above disclaimer, this paragraph, and appropriate citations appear in all copies, modifications, and distributions.



Treatment Options: **Green** = 1<sup>st</sup> line **Yellow** = 2<sup>nd</sup> line **Orange** = 3<sup>rd</sup> line **👤** = May require renal dose adjustment  
NS Health Firstline (adults) <https://firstline.org/nsha> IWK Firstline (pediatrics) <https://firstline.org/iwk/>

